INTRODUCTION Print Section Listen The MitraClip (Abbott Laboratories, Chicago, IL) device offers a novel, percutaneous, transvenous, transcatheter approach for patients suffering from severe mitral regurgitation, despite maximal medical therapy, in…
SCOPE OF THE PROBLEM Print Section Listen Hypertrophic cardiomyopathy (HCM), defined clinically by the presence of hypertrophy of a nondilated left ventricle without loading conditions or other recognized causes of…
INTRODUCTION Print Section Listen History The treatment of venous disease has changed dramatically in recent years with the advent of duplex ultrasound evaluation, minimally invasive treatments, and new thrombolytic drugs….
INTRODUCTION Print Section Listen Atrial fibrillation (AF) is the most common cardiac arrhythmia in adults with a current prevalence estimated at 1.5% to 2% of the general population. With the…
INTRODUCTION Print Section Listen Since the introduction of the 18-Fr CoreValve self-expanding transcatheter aortic valve replacement (TAVR), over 70,000 implants have been performed worldwide. The use of this self-expanding bioprosthesis…
BACKGROUND Print Section Listen Coronary atherectomy continues to be an important tool for percutaneous coronary intervention (PCI), particularly as the population ages and more patients present with complex calcified coronary…
INTERVENTION FOR BIFURCATION LESIONS Print Section Listen Bifurcation lesions have been reported to constitute 15% to 20% of all percutaneous coronary interventions (PCI).1 Since they are associated with an increased…
HISTORY AND RATIONALE OF THE PROCEDURE Print Section Listen Aortic stenosis (AS) is the most common acquired valvular disease in adults.1 The incidence of AS has steadily increased along with…
INTRODUCTION Print Section Listen The safety and efficacy of percutaneous coronary interventions (PCI) have been drastically improved by the introduction of bare metal stent (BMSs) in clinical practice.1 However, a…
INTRODUCTION Print Section Listen ST-segment elevation myocardial infarction (STEMI) composes approximately 25% to 40% of myocardial infarction (MI) presentations. There has been remarkable progress in the treatment and clinical outcomes…
